The Priority Review

Clinical trials Brief

Viking Therapeutics registers Phase 3 trial of VK2735 for weight management

The study, titled SUNRISE 1, is a Phase 3 randomized, double-blind, placebo-controlled trial of VK2735 administered orally for weight management. It plans to enroll 560 participants starting October 15, 2026, with primary completion projected for July 2028.

Primary source

ClinicalTrials.gov registry record, October 9, 2026

Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)

Read the source clinicaltrials.gov

By The Priority Review desk. Machine-summarized from the source above; not independently reported. How we use automation